



































GC Gene Polymorphism and Unbound Serum Retinol-
Binding Protein 4 Are Related to the Risk of Insulin
Resistance in Patients With Chronic Hepatitis C
A Prospective Cross-Sectional Study
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and José M. Ladero, MD, PhD
Abstract: Insulin resistance (IR) is found in chronic hepatitis C (CHC)
more frequently than in other chronic liver diseases.
Prospective cross-sectional study to evaluate a wide multitest panel
to identify factors related with IR in CHC and their possible interactions.
In 76 patients with CHC we performed a series of routine laboratory
analysis as well as specifically designed serum biochemical tests
[retinol, retinol-binding protein 4 (RBP4), 25-OH vitamin D, Vitamin
E, lipopolysaccharide-binding protein (LBP), interleukin-6 (IL-6), and
cystatin C]. The single nucleotide polymorphisms rs7041 and rs4588
GC-DBP (group-specific component-Vitamin D-binding protein),
rs738409 PNPLA3 (patatin-like phospholipase domain containing 3),
and rs12979860 IL28B (interleukin-28 B) genes were determined.
Insulin sensitivity was established with the HOMA-IR and IR was
diagnosed when HOMA-IR> 3. Fibrosis staging was assessed with
liver biopsy or transient elastography.
After backward logistic regression analysis, independent variables
associated with IR were Gc1s/Gc1s DBP phenotype, that results from the
homozygous carriage of the rs7041G/rs4588C haplotype (P¼ 0.033); low
retinol/RBP4 ratio, reflecting a greater rate of unbound RBP4 (P¼ 0.005);
older age (P¼ 0.01); high serum tryglicerides (P¼ 0.026); and advanced
(F3–F4) fibrosis stage. The AUROC provided by the multivariate model
was 0.950 (95% CI¼ 0.906–0.993).
In addition to previously known ones, the Gc1s/Gc1s phenotype
variant of DBP and the unbound fraction of plasma RBP4 may be
considered as factors related with the incidence, and possibly the risk,
of IR in CHC patients.
(Medicine 95(10):e3019)
Abbreviations: AUROC = area under operating curve, CHC =
chronic hepatitis C, DBP = Vitamin D-binding (protein-gene), GC =
group-specific component (protein–gene), HCC = hepatocellular
carcinoma, HCV = hepatitis C virus, HOMA-IR = homeostasis
model assessment of insulin resistance, IL28B = interleukin 28B
gene, IL-6 = interleukin 6, IQ = interquartilic, IR = insulin
resistance, LBP = lipopolysaccharide-binding protein, MS =
metabolic syndrome, NAFLD = nonalcoholic fatty liver disease,
NASH = nonalcoholic steatohepatitis, PNPLA3 = patatin-like
phosphatase domain containing gene, RBP4 = retinol-binding
protein 4, SNPs = single nucleotide polymorphisms, TNF-a =
tumor necrosis factor a.
INTRODUCTION
I nsulin resistance (IR) is more frequent in chronic hepatitis C(CHC) than in other chronic liver diseases.1 Hepatitis C virus
(HCV) chronic infection directly causes IR by interfering with
insulin signaling cascade,2 mainly through the interaction
between the HCV core protein at several steps of this cascade,3,4
but also by upregulating the production of proinflammatory
cytokines, such as tumor necrosis factor a (TNF-a) and inter-
leukin-6 (IL-6). IR in CHC has been related with the pro-
gression of liver fibrosis in CHC,1 with a lower rate of success
of interferon-based therapy,5 and with a greater risk of devel-
oping hepatocellular carcinoma (HCC).6 IR is the key factor for
developing the so called ‘‘metabolic syndrome’’ (MS). MS is
characterized by a constellation of cardiovascular risk-factors
and morbidities that include the presence of at least three of the
following components: elevated fasting glucose, elevated tri-
glycerides, elevated blood pressure, elevated waist circumfer-
ence, and low high-density lipoprotein (HDL) cholesterol.7,8
MS is associated with a chronic low-grade inflammatory
estate.9 Nonalcoholic fatty liver disease (NAFLD) is considered
as the hepatic manifestation of the metabolic syndrome.10
Therefore, it is easy to hypothesize that IR, NAFLD,
Editor: Wenyu Lin.
Received: November 26, 2015; revised: February 9, 2016; accepted:
February 11, 2016.
From the Services of Gastroenterology (BM-M, MJD-M, JML), Clinical
Laboratory (MJT, MCC), and Clinical Epidemiology (CE), Hospital
Clı́nico San Carlos, Instituto de Investigación Sanitaria del Hospital
Clı́nico San Carlos (IdISSC), Madrid, Spain (CF), Department of
Pharmacology, Universidad de Extremadura (EG-M, GEN, JAA), Labora-
tory of Molecular Genetics, Hospital de Terrassa, Terrassa, Barcelona,
Spain (MC), and Department of Medicine, Universidad Complutense,
Madrid, Spain (MJD-M, JML).
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derangements of serum lipid profile and a wide range of
nonspecific inflammatory markers (ie, reactive C protein or
IL-6) are interdependent phenomena although it may be diffi-
cult to establish which is (or are) the primary pathogenic
event(s) for IR and which others are consequences or simply
biochemical markers of IR, MS, and NAFLD.
Several GWAS in patients with CHC have identified a
wide range of single nucleotide polymorphisms (SNPs) which
have been located to genes related to many aspects of the natural
history of chronic HCV infection.11 Among them, the IL28B
rs12979860 CT polymorphism has been shown to strongly
influence the rate of both spontaneous and IFN-induced viral
clearance, probably by inducing differences in the baseline
expression of IFN-activated genes.12 A strong association
between rs738409 CG SNP at the PNPLA3 (patatin-like phos-
pholipase domain containing 3) and steatosis of the liver was
originally described in patients with NAFLD13 and its more
severe form (NASH—nonalcoholic steatohepatitis),14 but it has
been also found in patients with CHC.15
Vitamin D exerts immunomodulatory effects in CHC.16
The synthesis, transport, and physiological effects of Vitamin D
depend on the sequential function of several enzymatic path-
ways that are coded by highly polymorphic genes.17 In a
previous study we analyzed the influence of polymorphisms
at CYP27B1 gene—that regulates the renal 1-hydroxylation of
25-OH-Vitamin D)—and VDR gene—that codes for the vitamin
D transmembrane receptor—on the response to IFN-based
therapy.18 Vitamin D-binding protein (DBP), also known as
group-specific component protein (Gc) is the major serum
transporter protein for Vitamin D.19 The Gc or VDR gene is
polymorphic at 2 codon in exon 11 which give rise to 3 variants
of the gene product, called respectively Gc 1F, Gc 1s, and Gc
2.20 A possible association of this polymorphism with IR in
otherwise healthy subjects21 and with gestational diabetes
mellitus22 has been reported.
The aim of this study has been to explore the possible
association of polymorphic traits at Gc, PNPLA3, and IL28B
genes with IR in patients with CHC and to detect if any
interaction exists among them and a wide range of metabolic,
inflammatory, biochemical, and virological parameters.
PATIENTS AND METHODS
This is a prospective cross-sectional study including
chronically HCV-infected outpatients attending to our Liver
Unit from September 2013 to May 2014. In these patients, visits
are scheduled at a 6 months interval, and therefore, nearly all the
possible candidates were reviewed during the inclusion period.
Inclusion criteria were active chronic infection with HCV for
more than 6 months; known METAVIR stage of liver fibrosis23
disclosed by liver histology or transient elastography (for
Fibroscan1 staging we have used the cutoff points proposed
by Castera et al24) within the previous 12 months, and written
informed consent. Exclusion criteria were coinfection with
hepatitis B and/or human immunodeficiency viruses; current
drinking of >40 g/day of ethanol; any anti-HCV therapy in the
previous 12 months; diabetes mellitus; estimated glomerular
filtrate <60 mL/min/1.73 m2 and, decompensated cirrhosis
(criteria of decompensation were current or past ascites, hepatic
encephalopathy, bleeding varices, hepatocellular carcinoma,
and total serum bilirubin >3.0 mg/dl. Ascites were excluded
with ultrasonography performed within the previous month. All
patients provided written informed consent according with the
Declaration of Helsinki. The study was approved by the Ethics
Committee of the Hospital Clı́nico San Carlos, Madrid, Spain.
For each patient, all the analytical studies were performed
in the same day. A venous blood sample was collected after
overnight fast using a Vacutainer system (Becton Dickinson1,
Franklin Lakes, NJ). After 30 minutes, blood samples were
centrifuged during 10 minutes in a refrigerated centrifuge and
serum samples were stored at 48C or at 808 C until analysis.
Height and body weight were measured to estimate the body
mass index (weight in kg/height in m2).
Routine hematological, biochemical, and virological
analysis were performed by standard tests at our laboratories
as described elsewhere.25 The whole relationship of performed
determinations is shown in supplementary material (Table S1,
http://links.lww.com/MD/A749). Methods specifically per-
formed for this study were as follows: serum retinol and
tocopherol measurements were performed using a Vitamin
A-E kit from Chromsystems Diagnostics1 (Munich, Germany)
on a Shidmazu HPLC with UV detection at 325 and 295 nm.
The calibration standard is traceable to NIST 968e reference
material. Total 25(OH) vitamin D determination was measured
by a competitive direct immunoassay using chemoluminiscency
on an Architect i1000 analyzer (Abbott Diagnostics, Wiesba-
den, Germany). Retinol binding protein (RBP) and cystatin C
were measured by immunonephelometry on a BN Prospec
analyzer (Siemens Healthcare Diagnostics, Marburg,
Germany). Serum creatinine was measured by means of the
modified kinetic Jaffé method using a Beckman Coulter AU
5400 (Beckman Coulter, Brea, CA). Insulin levels were ana-
lyzed with an immunoassay IMMULITE 2000 Insulin (Sie-
mens1) and the HOMA-IR (Homeostasis Model Assessment)
was calculated according to the formula:
Fasting glucose ðmg=dlÞ  Fasting Insulin ðm uUI=mlÞ
405
A HOMA-IR> 3 was considered as an indicator of IR,
according with Moucari et al.26
LBP (lipopolysaccharide-binding protein) was measured
in serum with a solid-phase 2-site chemiluminescent immuno-
metric assay in an Immulite 1000 analyzer (Siemens Healthcare
Diagnostics) and the IL6 was performed with an electroche-
miluminescence immunoassay ‘‘ECLIA’’ in a Cobas E4111
(Roche Diagnostics, Basel, Switzerland).
Four SNPs were studied by means of TaqMan probes
(Thermo Fisher Scientific, Alcobendas, Madrid, Spain). These
included the SNP rs12979860, corresponding to the IL28B gene,
rs738409 corresponding to the PNPLA3 gene, and 2 SNPs
corresponding to the Gc gene, designated as rs7041 and
rs4588. These SNPs were selected on the basis of their allele
frequencies and clinical associations. Commercial primers were
used for the detection of the SNPs (C___7820464_10,
C___7241_10, C___3133594_30, and C___8278879_10,
respectively; Thermo Fisher Scientific). The detection was
carried out by qPCR in an Eppendorf Realplex thermocycler
(Eppendorf, Madrid, Spain). The amplification conditions were
as follows: After a denaturation time of 10 minutes at 968C, 45
cycles of 928C 15 seconds 608C 90 seconds were carried out and
fluorescence was measured at the end of every cycle and at
endpoint. All samples were determined by triplicate and geno-
types were assigned both, by the gene identification software
(RealPlex 2.0, Eppendorf) and by analysis of the reference cycle
number for each fluorescence curve, calculated by the use of
CalQPlex algorithm (Eppendorf).
For technical validation purposes, the amplified fragments
for 20 individuals carrying every possible genotype were
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sequenced, and in all cases the genotypes fully corresponded
with those detected with fluorescent probes.
Haplotype reconstruction for the GC SNPs was performed
using the program PHASE v2.1.1.27
We used the default model for recombination rate variation
with 1000 iterations, 500 burn-in iterations and a thinning
interval of 1 as described elsewhere.28
Fibrosis stage was established by liver biopsy in 30
patients and by transient elastography in the remaining 46
and was categorized in 4 (1–4) METAVIR categories, as
transient elastography does not discriminate between F0
and F1. Liver steatosis was defined, but not graded, by the
presence of fat in the liver biopsy, when available, or of a
pattern suggestive of steatosis in ultrasonography in the
remaining cases.
Statistical Analysis
Continuous variables, expressed as median and inter-
quartile (IQ) range, were compared with the Student’ t test or
the Mann–Whitney U test, each when adequate, depending
on their Gaussian distribution. Categorical variables,
expressed as count and percentage, were compared with
the x2 or the Fisher exact tests, each when appropriate,
and the effect of differences was established by calculating
the odds ratio with the 95% confidence interval. A P-
value< 0.05 or a confidence interval not including the unit
were considered significant. A stepwise logistic regression
analysis was performed to evaluate the independent factors
associated with IR by analyzing the covariants with P< 0.05
in the univariate analysis. The statistical analysis was carried
out with the SPSS software 22.0 (SPSS, Inc., Chicago, IL)
and with EpiDat 3.1 software (Junta de Galicia, Spain) for
specific tests.
RESULTS
A total of 81 patients who satisfied all the requisites to be
included were asked to participate in the study. One patient
refused to provide a blood sample for genetic studies, in a
second patient the serum samples for nonroutine biochemical
analysis were lost and in 3 patients DNA amplification failed.
The remaining 76 patients (36 male, median age 55 years, IQ
range 49–63.5) were included in the study and their data were
fully available for analysis. All patients were white Spaniards of
Spanish European ancestry, mainly from Central and Southern
peninsular Spain.
Table S1 (see Supplementary Material online, http://
links.lww.com/MD/A749) shows the median values with IQ
range of all the variables included in the study in the whole
group and the comparative analysis between patients without
(HOMA-IR 3, n¼ 34) and with (HOMA-IR 3, n¼ 42) IR.26
Table 1 is limited to those results showing significant differ-
ences in the univariate analysis. Sixty-five patients (85.5%)
were infected with HCV genotype 1 (mostly 1b) and 5 (6.6%)
with genotype 3. Viral load was classified as low (400,000 IU/
mL) in 14 patients versus high (>400,000 IU/mL) in 62
patients, according to Witthoft et al.29
The distribution of the studied genetic polymorphisms is
shown in Table 2, as are comparisons between subgroups
defined according to the IR status. In the univariate analysis,
no differences were found in the distribution of the IL28B and
PNPLA3 SNPs. Both polymorphisms were in Hardy–Weinberg
equilibrium and no linkage disequilibrium was found between
them. The allele frequencies of the studied SNP at the IL28B
gene were consistent with those previously reported among
Spaniards.30,31
There was a significant excess of patients carrying the
Gc1s/Gc1s DBP phenotype, that is defined by the homozygosity












Age (years) 55 (48.3–63.8) 53 (45.8–60.5) 57.5 (49.8–66.0) 0.071
Male gender, n (%) 36 (47.4) 13 (38.2) 23 (54.8) 0.284
BMI 26.3 (23.3–28.6) 23.6 (22.0–26.4) 27.2 (25.4–29.3) <0.001
LBP (mg/dL) 7.27 (5.72–8.57) 6.73 (5.34–7.83) 7.61 (6.43–10.03) 0.018
IL6y (pg/mL) 3.51 (2.57–5.62) 2.98 (1.80–4.01) 4.72 (2.89–6.46) 0.003
Vitamin B12 (pg/mL) 412 (286–512) 374 (282–451) 435 (287–569) 0.025
Cystatin C (mg/dL) 0.93 (0.80–1.03) 0.84 (0.75–0.95) 0.97 (0.90–1.10) <0.001
Uric acid (mg/dL) 5.30 (4.53–6.30) 4.65 (4.15–5.23) 5.95 (5.26–6.63) < 0.001
ASTy (U/L) 51 (38–80) 47 (35–58) 59 (43–114) 0.020
GGTy (U/L) 54 (33–106) 40 (30–75) 80 (45–145) 0.008
HDL-cholesterol (mg/dL) 55 (44–67) 60 (47–70) 49 (43–63) 0.049
Triglycerides (mg/dL) 85 (72–135) 78 (66–106) 95 (75–144) 0.010
TSHy (IU/mL) 1.51 (1.04–2.37) 1.28 (0.96–1.79) 1.72 (1.30–2.55) 0.039
Vitamin A/RBP ratioy 0.73 (0.67–0.81) 0.79 (0.72–0.85) 0.70 (0.62–0.76) <0.001
Vitamin E/total lipid ratio 2.61 (2.34–2.87) 2.72 (2.57–2.99) 2.41 (2.19–2.73) 0.029
Fibrosis stage (0–2 vs 3–4) 47/29 28/6 19/23 0.002
BMI¼ body mass index, HDL¼ high-density lipoprotein, HOMA¼ homeostasis model assessment, IL6¼ interleukin-6, LBP¼ lipopolysacchar-
lipopolysaccharide binding protein, RBP¼ retinol-binding protein, TSH¼ thyroid stimulating hormone.
Continuous variables are shown as median (interquartile range).
yContinuous variables not normally distributed.
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for the biallelic haplotype rs7041G/rs4588C at the exon 11 of
the Gc (DBP) gene,20 in the group of patients with IR
(P¼ 0.031). However, 25(OH) vitamin D serum levels were
not related with the Gc phenotype (Gc1s/Gc1s¼ 23.8 ng/dl
[IQR 17.9–31.4] vs non Gc1S/Gc1S¼ 21.8 ng/dl [IQR 14.4–
30.1], P¼ 0.342).
The carrier state of the rs738409G allele of the PNPLA3
gene was not related with presumptive inflammatory markers,
both direct (LBP, IL-6, and serum cystatin C), and inverse
(prealbumin and RBP4), nor with metabolic parameters related
to the metabolic syndrome (blood lipids, uric acid, serum
ferritin, TSH, and T4) (data not shown). The stage of fibrosis
was established by liver biopsy in 30 patients and transient
elastography in the remaining 46. There was a nonsignificant
excess of more advanced stages of fibrosis (F3–F4) among
carriers of the rs738409 G allele (P¼ 0.15) and all homozygous
carriers of this allele had advanced fibrosis. The rate of roughly
estimated steatosis of the liver was not related to the PNPLA3
polymorphism (data not shown).
All the parameters related with IR in the univariate
analyses shown in Tables 1 and 2 were included in the multi-
variate analysis. Only 5 variables (older age, higher triglycer-
ide levels, lower vitamin A/RBP ratio, advanced fibrosis stage,
and Gc1s/Gc1s phenotype) were significantly related to the
risk of IR (Table 3). Figure 1 shows the receiver operating
characteristic (ROC) curve provided by the model constructed
to establish predictive values for IR (AUROC¼ 0.950, 95% CI:
0.906–0.993).
DISCUSSION
Up to our knowledge this is the first study that shows an
independent relation between a well-known polymorphic trait at
the Gc gene, also known as the DBP gene, and the risk of IR in
patients with CHC. Patients carrying the Gc1s/Gc1s protein
phenotype had significantly higher values of HOMA-IR
(P¼ 0.002) and—most important—a greater percentage of
cases with defined insulin resistance (HOMA-IR> 3).
The association of IR with the Gc gene polymorphism has
been studied in several ethnic groups, mostly of non-Caucasian
origin. This is important because the distribution of this poly-
morphism shows a great interethnic variability and results
are not comparable. Moreover, most reports did not include
the analysis of the HOMA index, but only considered blood
glucose or insulin levels, both fasting and after oral glucose
tolerance test, separately,32–34 with the exception of Hirai et al21
in their study on 82 Japanese subjects with normal glucose
tolerance; only 6 of these patients carried the Gc1s/Gc1s
phenotype, but HOMA was significantly higher in them than
in patients with Gc1f/Gc1f phenotype, used as reference and
that was present only in 1 patient of our group.
Hepatocellular carcinoma (HCC) is a frequent compli-
cation of HCV-induced CHC in advanced, mainly cirrhotic,
stage. Lange et al35 studied the rs22822679 SNP at the Gc gene
in CHC patients with and without HCC and found an excess of
the minor G allele, that has some influence on the serum levels
of 25(OH) vitamin D and that is strong linkage disequilibrium
with the rs7041 polymorphism included in our study.36 Unfor-
tunately, these authors did not analyze aspects related with
glucose metabolism in their control group of 4325 CHC patients
without HCC.
A second interesting finding of our study is the significant
relation between IR and low values of the retinol-to-RBP4 ratio.
Retinol binding protein 4 transports 95% of serum retinol37 and
both parameters are strongly correlated (r¼ 0.884 in our study).
Hence, the serum level of retinol strictly depends on the hepatic







(N¼ 42) P value
DBP phenotype Gc1s/Gc1s
(yes/no)
23/53 6/28 17/25 0.031
PNPLA3 rs738409








PNPLA3 rs738409 G allele
carrier, n (%)
36 (47.4) 15 (44.1) 21 (50.0) 0.61
IL28B rs12979860








DBP¼D-binding protein, HOMA¼ homeostasis model assessment, PNPLA3¼ (patatin-like phospholipase domain containing 3).
TABLE 3. Variables Significantly Related to Insulin Resistance in the Multivariate Analysis
Variable P (Univariate) 95% CI P (Multivariate)
Age (y) 0.071 1.031–1.269 0.011
Triglycerides (mg/dL) 0.01 1.002–1.038 0.026
Vitamin A/RBP ratio <0.001 0.000–0.003 0.005
Fibrosis stage (0–2 vs 3–4) 0.001 1.159–39.171 0.034
Gc1s/Gc1s (yes/no) 0.031 1.203–75.02 0.033
CI¼ confidence interval, RBP¼ retinol-binding protein.
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synthesis and excretion of RBP4, that, in turn, decreases in
parallel to increasing liver damage38–40 and inflammation.41 It
has been suggested that a retinol-to-RBP4 ratio <0.8 reflects
retinol deficiency better than serum retinol level.42 However,
RBP4 has been recently identified as an adipokine and a relative
excess of RBP4 in relation to retinol (ie, an increase of the free
or unbound fraction of RBP4) may reflect IR instead of retinol
deficiency,43 a possibility that is in accordance with our finding
of higher levels of elevated unbound RBP4 that were indepen-
dent of the vitamin A level and the fibrosis stage of CHC, but
closely correlated with serum IL-6, a well-known inflammatory
cytokine (rho¼0.515 in our study).
The remaining factors that we have found to be related
with IR should be commented in brief. Increasing age is
associated with the emergence of MS and IR, and not only
with the natural, and highly variable, course of HCV chronic
infection.44 A high plasma triglyceride level is one of the most
conspicuous metabolic findings in MS,8 whereas high uric acid
levels are frequently found in MS and linked to insulin sensi-
tivity index, probably through its close relationship with trigly-
ceride levels,45 thus explaining why uric acid it is in the limit of
significance in the multivariate analysis and excluded from the
predictive model for IR that we propose in this study. Our
results also confirm that IR is associated with an accelerate
progression of liver fibrosis in CHC.1 Two independent
groups46,47 found lower values for HOMA-IR in nondiabetic
CHC patients carrying the rs12979860 CC IL28B genotype than
in carriers of the other two possible genotypes (CT and TT), but
our results and those of Degasperi et al48 and Lemoine et al49 do
not confirm this relationship.
Our study has several limitations. The most important is
the small sample size, although more than 95% of adequate
available patients were included. On the other side, the stage of
fibrosis was established by 2 different methods (liver biopsy and
transient elastography) not always coincidental. In addition, the
lack of histological study in 40 cases impeded us to know the
incidence and degree of liver steatosis to evaluate the suggested
role of the PNPLA3 polymorphism on the risk of developing this
important aspect of the liver damage in CHC.15 In spite of these
drawbacks, we can conclude that the novel findings provided by
this study are that a common polymorphic trait at the DBP4
gene, causing the expression of the Gc1s/Gc1s phenotype, and
the possible overexpression of RBP4 (or alternatively, a relative
deficiency of vitamin A) are linked to the risk of developing IR
in patients with CHC.
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